Modelling the impact of different testing strategies for HCV infection in switzerland

Intervention: HCV RNA testing at the time of receipt of a positive HCV antibody result Comparison: HCV RNA test in the context of HCV care as part of assessment for HCV therapy

Before the development of a cell culture system for HCV (HCVcc) in 2005 [2–4], selectable replicon systems [5] and retrovirus-based pseudotyped particles (HCVpp) [6–8] were major

HCV RNA values on DBS specimens were compared to serum HCV RNA values quantified in matched serum samples collected in 37 HCV-infected patients followed in the Montpellier

cytosolic domain required for HCV infection and OCLN cell surface expression. Moreover, it emphasizes the specific involvement of the distal C-terminus domain of

Law itz reports receiving consulting fees from AbbVie, Achillion Pharmaceuticals, Idenix Pharmaceuticals, Janssen Pharmaceuticals, Novartis, Merck, Vertex Pharmaceuticals,

Patients randomly assigned to group 2 (response-guided therapy) received peginterferon–ribavirin plus bo- ceprevir for a total of 24 weeks after the lead-in period; if HCV RNA

Patients were random- ly assigned to one of four treatment groups: the T12PR24 group, which received telaprevir (VX-950, Vertex Pharmaceuticals), peginterferon alfa-2a

direct sequence analysis of a portion of the nonstructural (NS) 5B-coding gene followed by phylogenetic analysis. The ability of the following commercial assays to correctly